HeXun Biosciences has successfully implemented a dual strategy focused on R&D and CDMO (Contract Development and Manufacturing Organization), driving impressive financial results. As of August, the company’s revenue reached NT$182 million, a year-on-year increase of 262%, with an EPS of NT$1.68 in the first half of the year, making HeXun the runner-up among cell therapy stocks. Chairman Cheng-han Wen stated that the company will accelerate international collaborations, potentially involving equity partnerships or establishing overseas production facilities.
To expand its global market presence, attract partners, and recruit top talent, HeXun will hold a special shareholder meeting on the 27th to elect a new board of directors. The nominated board members come from various fields, including new drug development, medical devices, distribution, and finance, highlighting HeXun's plans to build a robust team to lead its efforts in CMO/CDMO, exosome product sales, and new drug development. The company aims to leverage Taiwan's MIT technology to compete on the global stage.
HeXun’s revenue of NT$182 million in the first eight months of the year marks a record high, with a net profit of NT$77.27 million in the first half and an EPS of NT$1.68, also a new annual record, second only to Chime Biologics in the cell therapy sector.
Cheng-han Wen highlighted that HeXun utilizes advanced human-derived umbilical mesenchymal stem cell cultivation technology and GTP-certified cell preparation facilities. The company has established production platforms for immune cells and stem cells with capacities exceeding 10 liters, exosome production exceeding 100 liters, and a regenerative medicine manufacturing capacity exceeding 10,000 doses per day. This capability extends to raw material development, IND (Investigational New Drug) applications, and the production of clinical trial drugs, covering a range of CMO/CDMO services that allow HeXun to collaborate with clients in global market expansion.
He also mentioned that HeXun's "mesenchymal stem cell drug production technology" has been licensed to Ji Yan Biomedical for a total value of USD 6 million (approximately NT$192 million). The two companies are jointly developing umbilical cord-derived mesenchymal stem cell exosomes, which Ji Yan Biomedical will apply in wound healing treatments and the medical aesthetics field. This licensing agreement has contributed approximately NT$100 million to HeXun's revenue in the first eight months.
Looking ahead, HeXun is optimistic about increasing CDMO orders for cell processing and exosomes, with expectations that its performance in the second half of the year will surpass that of the first half.
Resource (mandarin): 和迅雙軌並進 獲利耀眼 董事長温政翰：將加速國際合作
